PBM Trade Group Challenges Illinois Drug Pricing Transparency Law on ERISA Grounds
Key Takeaways
- The Pharmaceutical Care Management Association (PCMA) has filed a federal lawsuit against Illinois challenging portions of the state’s Prescription Drug Affordability Act (PDAA), arguing that key pharmacy benefit manager (PBM) transparency and network-design provisions are preempted by the Employee Retirement Income Security Act (ERISA).
- The case adds to a growing wave of litigation testing the extent to which states can regulate PBMs while employer-sponsored health plans remain subject to federal oversight.
- A court ruling could have implications far beyond Illinois, potentially shaping future PBM transparency, reporting, and anti-steering laws nationwide.
The PCMA, the national trade association representing PBMs, has filed suit against Illinois officials seeking to block portions of the state's PDAA, arguing that the law improperly regulates employer-sponsored health plans governed by federal law.1
The lawsuit, filed in the US District Court for the Central District of Illinois, focuses on 2 key components of the PDAA: extensive reporting requirements for PBMs and restrictions on pharmacy network designs that allegedly steer patients toward affiliated pharmacies.1
The challenge represents the latest chapter in an ongoing legal and regulatory battle over state efforts to increase oversight of PBMs, which play a central role in negotiating drug prices, administering pharmacy benefits, and managing prescription drug networks.
PCMA Alleges Illinois Law Conflicts With Federal Benefits Law
According to the complaint, PCMA argues that the Illinois law imposes requirements that are preempted by ERISA, the federal statute that establishes uniform standards for employer-sponsored benefit plans.1
The trade group contends that compliance with the Illinois requirements would force PBMs to create state-specific administrative systems and benefit structures for ERISA-covered plans operating in Illinois, undermining ERISA's objective of maintaining nationally uniform plan administration.1
The complaint seeks declaratory and injunctive relief preventing enforcement of the challenged provisions against PBMs serving ERISA-governed plans.1
ERISA preemption has long served as a key legal battleground in disputes involving state regulation of health benefits, and courts have frequently been asked to determine where state authority ends and federal oversight begins.
Transparency Requirements at the Center of the Dispute
One of the primary provisions challenged by PCMA involves Illinois's new reporting obligations.
According to Healthcare Dive, the PDAA would require PBMs to submit annual reports containing detailed information regarding drug pricing, reimbursement practices, and manufacturer rebates.2
Among the disclosures reportedly required are the following:
- Amounts paid by health plans to PBMs
- Amounts paid by PBMs to pharmacies
- Manufacturer rebate amounts associated with specific transactions
- Contracts between PBMs and plan sponsors or insurers2
Supporters of the law have argued that greater transparency is necessary to provide policymakers and plan sponsors with better insight into prescription drug pricing and reimbursement practices.
PCMA, however, argues that the disclosures involve highly confidential business information and may overlap with federal reporting requirements enacted by Congress, creating additional administrative burdens.1,2
Illinois Seeks to Limit Pharmacy Steering
The lawsuit also challenges provisions designed to restrict what critics describe as "patient steering" by vertically integrated PBMs.
The law seeks to prevent PBMs from designing pharmacy networks in ways that allegedly favor affiliated pharmacies over competing providers.2,3
Supporters of such restrictions argue that vertically integrated PBMs may possess incentives to direct patients toward pharmacies owned by related corporate entities, potentially limiting competition and patient choice.
PBMs have countered that preferred pharmacy networks can help lower costs, improve adherence, and enhance care coordination by directing patients to pharmacies that meet certain performance or pricing criteria.2
According to Healthcare Dive, PCMA argues that the Illinois restrictions would limit PBMs' ability to use network design strategies intended to reduce costs and improve outcomes.2
Part of a Broader National PBM Reform Movement
The Illinois litigation emerges amid increasing state and federal scrutiny of PBMs.
Over the past several years, lawmakers across the country have advanced legislation addressing the following:
- Drug pricing transparency
- Pharmacy reimbursement practices
- Spread pricing
- Pharmacy ownership arrangements
- Patient steering concerns
As Becker's Hospital Review noted, Illinois joins a growing number of states pursuing more aggressive oversight of PBM business practices, while industry groups increasingly turn to federal courts to challenge those measures.3
The lawsuit follows closely behind a separate PCMA challenge to a Tennessee law that restricts PBM ownership of pharmacies, illustrating the industry's broader legal strategy in response to state-level reforms.3
Implications for Health Plans, PBMs, and Pharmacies
The outcome of the case could have significant implications for multiple stakeholders throughout the pharmaceutical supply chain.
For PBMs and employer-sponsored plans, a ruling in favor of PCMA could reinforce ERISA's role as a shield against certain state regulatory requirements.
For states and pharmacy advocates, a decision upholding the Illinois law could provide a roadmap for additional transparency and anti-steering measures aimed at increasing oversight of PBM operations.
The case may also influence future debates surrounding:
- Drug pricing transparency
- Confidentiality of rebate arrangements
- Pharmacy network design
- State authority over prescription drug benefit administration
Looking Ahead
As states continue to pursue legislative reforms targeting PBM practices, courts will likely play an increasingly important role in defining the boundaries between state regulatory authority and federal oversight under ERISA.
The Illinois challenge represents one of the most significant recent tests of those boundaries and may help determine how aggressively states can regulate PBMs in the future.
References
- Pharmaceutical Care Management Association v Gillespie. Complaint for Declaratory and Injunctive Relief, No. 3:26-cv-03200 (CD Ill June 16, 2026). Accessed June 24, 2026. https://benefitslink.com/src/ctop/pcma-v-gillespi-cdill-complaint-06162026.pdf
- Parduhn RP. PCMA sues Illinois over Prescription Drug Affordability Act, arguing PBMs are exempt from key provisions under ERISA. Healthcare Dive. Published June 18, 2026. Accessed June 24, 2026. https://www.healthcaredive.com/news/pcma-sues-illinois-prescription-drug-affordability-act-pbm/823195/
- Casolo E. PBMs take Tennessee, Illinois to federal court over pharmacy laws. Becker's Hospital Review. Published June 18, 2026. Accessed June 24, 2026. https://www.beckershospitalreview.com/pharmacy/pbms-take-tennessee-illinois-to-federal-court-over-pharmacy-laws/
